Neoadjuvant chemoimmunotherapy improves response rates in head and neck cancer.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41842604.
- Also identified by DOI 10.1158/1078-0432.CCR-25-4813.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite the recent approval of perioperative pembrolizumab for locally advanced, resectable head and neck squamous cell carcinoma, response rates to immunotherapy are low. A recent single-arm phase II trial of neoadjuvant nivolumab in combination with carboplatin and paclitaxel demonstrated improved pathologic response rates compared to either chemotherapy or immunotherapy alone.